ProMIS End Period Cash Flow vs Capital Expenditures Analysis
| PMN Stock | USD 0.92 0.11 10.68% |
ProMIS Neurosciences financial indicator trend analysis is much more than just breaking down ProMIS Neurosciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ProMIS Neurosciences is a good investment. Please check the relationship between ProMIS Neurosciences End Period Cash Flow and its Capital Expenditures accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.
End Period Cash Flow vs Capital Expenditures
End Period Cash Flow vs Capital Expenditures Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ProMIS Neurosciences End Period Cash Flow account and Capital Expenditures. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between ProMIS Neurosciences' End Period Cash Flow and Capital Expenditures is -0.29. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of ProMIS Neurosciences, assuming nothing else is changed. The correlation between historical values of ProMIS Neurosciences' End Period Cash Flow and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of ProMIS Neurosciences are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of End Period Cash Flow i.e., ProMIS Neurosciences' End Period Cash Flow and Capital Expenditures go up and down completely randomly.
Correlation Coefficient | -0.29 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
End Period Cash Flow
Capital Expenditures
Capital Expenditures are funds used by ProMIS Neurosciences to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of ProMIS Neurosciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most indicators from ProMIS Neurosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ProMIS Neurosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.At this time, ProMIS Neurosciences' Selling General Administrative is very stable compared to the past year. As of the 27th of November 2024, Issuance Of Capital Stock is likely to grow to about 24.4 M, while Sales General And Administrative To Revenue is likely to drop 348.08.
| 2021 | 2023 | 2024 (projected) | Cost Of Revenue | 5.9M | 10.4M | 11.3M | Interest Income | 4.7K | 5.4K | 5.7K |
ProMIS Neurosciences fundamental ratios Correlations
Click cells to compare fundamentals
ProMIS Neurosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ProMIS Neurosciences fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 2.1M | 1.4M | 22.4M | 9.4M | 18.0M | 18.9M | |
| Total Current Liabilities | 1.7M | 2.4M | 1.2M | 8.7M | 12.4M | 13.0M | |
| Total Stockholder Equity | 398.1K | (1.0M) | 7.2M | (1.8M) | 5.0M | 5.2M | |
| Property Plant And Equipment Net | 0.0 | 99.6K | 5.9K | 434.62 | 391.16 | 371.6 | |
| Net Debt | (1.7M) | (1.0M) | (16.5M) | (8.0M) | (16.7M) | (15.9M) | |
| Retained Earnings | (65.6M) | (71.2M) | (78.6M) | (108.7M) | (123.8M) | (117.6M) | |
| Accounts Payable | 465.0K | 437.5K | 409.0K | 3.0M | 10.4M | 10.9M | |
| Cash | 1.7M | 1.0M | 21.4M | 8.0M | 16.7M | 17.5M | |
| Non Current Assets Total | 48.3K | 144.2K | 40.8K | 28.6K | 25.8K | 24.5K | |
| Cash And Short Term Investments | 1.7M | 1.1M | 21.5M | 8.0M | 16.8M | 17.6M | |
| Net Receivables | 56.8K | 31.0K | 48.7K | 71.6K | 64.5K | 110.2K | |
| Common Stock Shares Outstanding | 4.3M | 4.8M | 5.8M | 7.5M | 12.3M | 12.9M | |
| Short Term Investments | 41.8K | 76.7K | 50.7K | 59.5K | 61.6K | 58.6K | |
| Liabilities And Stockholders Equity | 2.1M | 1.4M | 22.4M | 6.9M | 17.4M | 18.2M | |
| Non Current Liabilities Total | 1.1M | 437.5K | 14.1M | 1.9M | 683.9K | 649.7K | |
| Inventory | (56.8K) | (31.0K) | (48.7K) | (71.6K) | (64.5K) | (61.2K) | |
| Other Current Assets | 321.8K | 135.0K | 688.6K | 925.1K | 1.3M | 1.4M | |
| Other Stockholder Equity | 8.1M | 28.9M | 85.8M | 107.0M | 129.3M | 135.8M | |
| Total Liab | 1.7M | 2.4M | 15.3M | 8.7M | 13.1M | 13.7M | |
| Total Current Assets | 2.0M | 1.2M | 22.4M | 9.3M | 18.0M | 18.9M | |
| Accumulated Other Comprehensive Income | 8.9M | 9.1M | (237.6K) | (264.5K) | (491.8K) | (467.2K) | |
| Intangible Assets | 48.3K | 41.6K | 34.9K | 28.2K | 25.4K | 43.6K | |
| Other Current Liab | 1.2M | 1.4M | 765.9K | 3.4M | 2.0M | 2.1M | |
| Common Stock | 45.2M | 49.0M | 52.7M | 56.5M | 65.0M | 38.3M | |
| Good Will | (12.6K) | (14.6K) | (11.3K) | (9.0K) | (8.1K) | (8.5K) | |
| Net Tangible Assets | 349.8K | (1.1M) | 7.4M | (1.4M) | (1.6M) | (1.5M) | |
| Net Invested Capital | 304.8K | (796.7K) | 9.7M | (1.3M) | (1.5M) | (1.5M) | |
| Net Working Capital | 267.8K | (909.8K) | 16.7M | 490.4K | 564.0K | 535.8K |
Pair Trading with ProMIS Neurosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProMIS Neurosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProMIS Neurosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with ProMIS Stock
| 0.84 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.62 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.81 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against ProMIS Stock
| 0.76 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.74 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.54 | ESLAW | Estrella Immunopharma | PairCorr |
| 0.52 | PHVS | Pharvaris BV | PairCorr |
| 0.5 | PMVP | Pmv Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to ProMIS Neurosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProMIS Neurosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProMIS Neurosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProMIS Neurosciences to buy it.
The correlation of ProMIS Neurosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProMIS Neurosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProMIS Neurosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProMIS Neurosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.04 | Revenue Per Share 0.001 | Return On Assets (4.81) | Return On Equity (10.99) |
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.